PROSION

Please note: The information displayed on this page might be outdated.
PROSION: A pharmaceutical drug discovery company offering proline derived modules (ProMs) as the world’s first proline-rich-motive (PRM) structure mimicking building blocks. Based on its disruptive ProM-platform, PROSION develops a new class of drugs and is able to address yet undruggable considered targets that are related to various indications. Among those targets is Ena/VASP, a marker of pancreatic & breast carcinogenesis and potential game-changer in oncology. For its first of many potential use-cases, PROSION has already shown a remarkable in vivo effect of its ProM-based anti-metastatic inhibitor – both in pancreatic and breast cancer xenograft rodent models.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Pre-Clinical Stage
Disease Space
Cardiovascular, Oncology
Finance
Pre-Revenues
Industry
Life Sciences, Pharmaceuticals, Specialty Pharmaceutical
Listing
Private
Market Cap
Private
Therapeutic Modalities
pi3k, Platform Technology, Small Molecule
Website:
Profiles:
Address:
Vitalisstraße 67
Cologne, 50827
Germany

Company Participants at Fall Private Company Showcase 2021

  • Slim Chiha, Co-founder & CEO

Upcoming Company Event Participation